Host chitinase 3-like-1 is a universal therapeutic target for SARS-CoV-2 viral variants in COVID-19.

Kamle, Suchitra; Ma, Bing; Lee, Chang Min; Schor, Gail; Zhou, Yang; Lee, Chun Geun; Elias, Jack A

Kamle, Suchitra; Ma, Bing; Lee, Chang Min; Schor, Gail; Zhou, Yang; Lee, Chun Geun; Elias, Jack A.

Afiliação

Kamle S; Department of Molecular Microbiology and Immunology, Brown University, Providence, United States.
Ma B; Department of Molecular Microbiology and Immunology, Brown University, Providence, United States.
Lee CM; Department of Molecular Microbiology and Immunology, Brown University, Providence, United States.
Schor G; Department of Molecular Microbiology and Immunology, Brown University, Providence, United States.
Zhou Y; Department of Molecular Microbiology and Immunology, Brown University, Providence, United States.
Lee CG; Department of Molecular Microbiology and Immunology, Brown University, Providence, United States.
Elias JA; Brown University, Providence, United States.

Elife ; 112022 06 23.

Article em En | MEDLINE | ID: mdl-35735790

Assuntos

Tratamento Farmacológico da COVID-19; Quitinases; Enzima de Conversão de Angiotensina 2; Quitinases/genética; Humanos; Peptidil Dipeptidase A/metabolismo; SARS-CoV-2/genética; Internalização do Vírus

Palavras-chave

CHI3L1; FRG; anti-CHI3L1 antibody; delta; infectious disease; kasugamycin; microbiology; omicron; viruses

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quitinases / Tratamento Farmacológico da COVID-19 Limite: Humans Idioma: En Revista: Elife Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google